Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$23.46M$23.46M+17.2% vs Q1 2021 Net Income-$63.89M-$63.89MN/M vs Q1 2021 EPS Diluted-$0.63-$0.63N/M vs Q1 2021 Operating Income-$62,923,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Free Cash Flowderived-$44,983,000N/M Margins · derivedOperating margin-268.2%−7.9 pt vs Q1 2021
Net margin-272.4%−9.5 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end